UC-MSC Therapeutic

About Arugula Sciences

Arugula Sciences is a private, clinical-stage biotech leveraging the therapeutic potential of umbilical cord-derived mesenchymal stem cells (UC-MSCs) and acellular products. The company's lead program, Signature Cord Prime™, is in an FDA Phase 1 trial for knee osteoarthritis, with another Phase 1 study approved for big toe osteoarthritis. Founded in 2018, Arugula is pre-revenue and is building a platform around perinatal tissue biologics to treat a range of degenerative conditions, positioning itself in the competitive but high-growth cell and gene therapy sector.

Therapeutic Areas